ORIGINAL RESEARCH article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1605653
An Investigation of the Relationship between sPD-1, sPD-L1 and Severe Pneumonia Patients Admitted to ICU and Its Clinical Significance
Provisionally accepted- 1Affiliated Hospital of Zunyi Medical University, Zunyi, China
- 2Affiliated Jinyang Hospital of Guizhou Medical University, Guiyang, Guizhou Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Soluble programmed cell death 1 (sPD-1) and its ligand (sPD-L1) have emerged as potential biomarkers for early identification and risk stratification in patients with SP. However, there is a lack of robust laboratory evidence supporting their clinical utility. This study aimed to explore the relationship between sPD-1/sPD-L1 levels and clinical outcomes in SP patients.Methods: This study included SP patients admitted to the Department of Critical Care Medicine at the Affiliated Hospital of Zunyi Medical University between November 2022 and December 2023. Patients were categorized into survivor and non-survivor groups based on 28-day clinical outcomes. Baseline characteristics and laboratory data were collected upon admission. Serum levels of sPD-1 and sPD-L1 were quantified using enzyme-linked immunosorbent assay. Cox regression analysis was performed to identify prognostic factors, and a nomogram was developed to predict outcomes. The predictive performance of sPD-1, sPD-L1, and their combined indices was evaluated using receiver operating characteristic (ROC) curve analysis.Results: A total of 125 patients with severe pneumonia (SP) were included in this study.Compared to survivors, non-survivors were older, had more severe disease (as indicated by higher SOFA and APACHE II scores), and exhibited lower body mass index (BMI), hemoglobin levels, lymphocyte counts, CALLY index, and albumin levels. Additionally, non-survivors showed significantly elevated levels of systemic inflammatory markers (NLR, PLR, MLR, CLR, CAR, and SII) and higher serum sPD-1 concentrations.Multivariate Cox regression analysis identified age, SOFA score, and sPD-1 levels as independent risk factors for poor prognosis in SP patients. RCS curves revealed a linear relationship between age, SOFA score, and the risk of poor prognosis. A nomogram incorporating age, SOFA score, and sPD-1 levels demonstrated strong predictive performance for 28-day mortality in SP patients, with an area under the AUC of 0.80. Incorporating sPD-1 measurements significantly improves the prognostic accuracy of both SOFA and APACHE II scores in critically ill patients.sPD-1 levels were significantly elevated in non-surviving SP patients, suggesting its potential role as a biomarker for disease severity and immune 3 / 17 dysregulation. The combination of sPD-1 with other clinical parameters may provide valuable insights into the prognosis and immune status of SP patients.
Keywords: Severe pneumonia, 28 day mortality rate, soluble PD1, SPDL1, prognosis
Received: 08 Apr 2025; Accepted: 05 Jun 2025.
Copyright: © 2025 Gao, Lu, Yu and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bao Fu, Affiliated Hospital of Zunyi Medical University, Zunyi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.